This post was originally published on this site Adding Velcade (bortezomib) to standard chemotherapy is well-tolerated but does not improve the survival outcomes of patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL), even after stratifying patients according to their cell of origin, a Phase 3 trial shows. The study, “Gene-expression profiling of bortezomib added to standard…
This post was originally published on this site A Phase 2 trial testing the investigational PARP inhibitor pamiparib in treating metastatic castration-resistant prostate cancer patients is using Epic Sciences‘ novel liquid biopsy assay to select those patients who are most likely to benefit from treatment, the company announced. Epic’s test is designed to collect circulating tumor…
This post was originally published on this site BioAtla and BeiGene entered into a collaboration agreement for the development, production, and commercialization of BioAtla’s BA3071, an investigational anti-CTLA-4 checkpoint blockade antibody. Checkpoint blockade therapies are based on the principle of removing the “brakes” of the immune system, in order to use the power of the…
This post was originally published on this site AstraZeneca is starting a collaboration with Daiichi Sankyo for the global production and commercialization of trastuzumab deruxtecan (DS-8201), a novel antibody-drug conjugate under clinical studies for the treatment of advanced HER2-positive breast cancer, and other types of solid tumors. The investigational therapy was granted fast track status by the…
This post was originally published on this site Despite a United States Preventive Services Task Force (USPSTF) 2012 conclusion that routine tests for prostate cancer are unnecessary, a prominent oncologist believes such screenings should be encouraged. Vladimir Ioffe, MD, a radiation oncologist with 21st Century Oncology, said prostate-specific antigen (PSA) screenings ought to be recommended…
This post was originally published on this site Women with invasive epithelial ovarian cancer have better survival rates at five years of diagnosis if they carry mutations in the BRCA1 and BRCA2 genes. However, this benefit decreases over 15 years of follow-up, according to a long-term study from Israel. The research, “Fifteen-year survival of invasive…
This post was originally published on this site Janssen Biotech is planning a new Phase 3 clinical trial to explore a combination of under-the-skin daratumumab plus Revlimid (lenalidomide) as a maintenance treatment for multiple myeloma patients who received an autologous stem cell transplant as front-line treatment. Specifically, the study is for patients who are positive for minimal…
This post was originally published on this site The Japan Ministry of Health, Labour and Welfare (MHLW) has granted Sakigake Designation to valemetostat, an investigational treatment for adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The designation is given to promising therapies and aims to accelerate their development and review process, as well as reduce…
This post was originally published on this site Vaccibody‘s VB10.NEO and Nektar Therapeutics‘ bempegaldesleukin (NKTR-214 or bempeg) work together to trigger a strong immune response against cancer cells, resulting in complete and durable tumor regression in a mouse model of colon cancer, a recent study says. The findings were featured in the poster, “Combination of neoantigen…
This post was originally published on this site It’s probably not back. But if it is, it’ll kill me. Every six months, I travel to the Bay Area for tests to see if my triple-negative breast cancer is back. It’s nerve-wracking. I’ve already decided I won’t do chemo again; not because I hated chemo —…
